4 results about "Αvβ3 integrin" patented technology

Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.

The invention discloses a tumor targeted diagnosis and treatment integrated system based on organic-inorganic dynamic assembly and a preparation method thereof, the system takes an aminated mesoporous nano-material as a carrier to load a chemotherapeutic drug and a photothermal agent, and realizes alpha v beta 3 integrin targeting through RGD peptide modification. And furthermore, sodium alginate (Alg-NB) grafted with N-(2-aminoethyl)-4-(4-(hydroxymethyl)-2-methoxy-5-nitrophenoxy) methyl butyrate (NB) with pH / NIR dual response is utilized, and through Schiff base reaction and calcium ion crosslinking coating, an intelligent nano diagnosis and treatment platform is formed. According to the invention, a'dynamic gating 'release mechanism is created for the first time, and time-space controllable drug release is realized. By integrating a photo-thermal / photodynamic, chemotherapy and active targeting triple synergistic treatment mode, an efficient anti-tumor effect is achieved. In addition, the system achieves the diagnosis and treatment integrated function in a breakthrough mode, has the near-infrared fluorescence imaging and thermal imaging guiding capacity, and provides support for precise treatment in an operation. The invention provides a new idea for a new generation of organic-inorganic dynamically assembled targeted integrated diagnosis and treatment system.

The invention discloses a linker compound of an integrin alpha v beta 3 inhibitor, which is shown as a formula (1) and can be used for a prodrug delivery system, or a tautomer, a mesomer, a raceme, an enantiomer, a diastereoisomer of the linker compound, or a mixture form of the linker compound, or a pharmaceutically acceptable salt, a prodrug or a solvate of the linker compound, and a synthesis method and application of the linker compound. The structure of the formula (1) comprises an alpha v beta 3 integrin antagonist, a connecting unit, a polyethylene glycol (PEG) spacer and a cytotoxic element. IA-LI-PD (1).

Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for αvβ3 integrin and / or αvβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin αvβ3, integrin αvβ5, or both integrin αvβ3 and integrin αvβ5. Compositions that include integrin targeting ligands and methods of use are also described.